The Top 200 Cannabis-Related Studies Published in 2025

These studies cover a wide spectrum of conditions, from autoimmune disorders and mental health issues to gastrointestinal diseases and metabolic dysfunction. In addition, researchers are increasingly turning their attention to cannabinoids beyond THC and CBD, such as CBG, THCV, and CBC. Many studies also focus on novel delivery systems—like oral dissolvable films, skin patches, and advanced emulsions—while investigating how marijuana may affect pain regulation, sleep quality, immune response, and emotional health. What follows is a detailed roundup of more than 200 marijuana-related studies released so far this year.

Analyzing data from over 25,000 UK Biobank participants, this study found that older cannabis users exhibited brain network activity reminiscent of younger individuals—particularly in subcortical–sensorimotor and subcortical–cerebellar connectivity—and also showed enhanced cognitive performance. While causality wasn’t established, findings suggest a possible neuroprotective role for cannabinoids and the endocannabinoid system in brain aging.

Published in Clinical Nephrology, this study analyzed patient data and found that cannabis use does not accelerate kidney function decline or increase the risk of chronic kidney disease, suggesting that cannabis may be safer for renal health than previously assumed.

This compelling case study, published in Integrative Cancer Therapies, recounts a patient with glioblastoma who achieved long-term remission following an integrative treatment involving medical cannabis, melatonin supplements, and ozone therapy.

Published in Dermatology and Therapy, this study demonstrated that topical application of cannabigerol (CBG) effectively reduced skin redness and inflammation in a rosacea model, highlighting its potential as a therapeutic topical agent for inflammatory skin issues.

Published in Journal of Cannabis Research, this study found that exposing a purple cannabis cultivar to cooler, constant temperatures (8 °C and 15 °C) significantly increased anthocyanin production—the compound responsible for purple coloration—without reducing flower weight or CBD content. In contrast, variable temperatures produced less pigment, but flower weight and CBD levels consistently rose with warmer cumulative growing conditions.

Published in Inflammatory Bowel Diseases, this survey revealed that a majority of patients with inflammatory bowel disease (IBD) report improvement in symptoms with cannabis or CBD use. Notably, about one in three respondents also indicated that cannabis helped reduce their opioid consumption.

Published in Journal of Substance Abuse Treatment, this study found that individuals with substance use disorders who used medical cannabis experienced enhanced quality of life and were more likely to reduce opioid use compared to those not using cannabis.

Published in Bioresource Technology, this study highlighted that the majority (90%) of hemp biomass from CBD production ends up as waste. However, converting this waste into bioenergy via anaerobic digestion presents a sustainable alternative, turning byproducts into a clean energy source.

Published in Journal of Clinical Neurology, this clinical trial found that a topical CBD gel significantly reduced migraine frequency and severity in individuals suffering from bruxism-related muscle pain—and also improved sleep quality in affected participants.

This research challenges assumptions about impulsivity in habitual cannabis users. In cognitive and physical tasks—including choosing which cup to retrieve in a proactive vs. reactive manner—chronic users performed on par with non-users and often demonstrated more proactive decision-making. Both groups also displayed similar cognitive control in structured tasks, despite users showing lower short-term memory on other assessments.

Surveying 7,648 individuals with eating disorders across Australia, the U.K., and the U.S., this study found that cannabis and psychedelics were perceived by respondents to be among the most effective treatments for managing eating disorder symptoms—whereas conventional psychotropics were typically viewed as less helpful. The study authors called for further clinical investigation into these substances’ therapeutic potential.

In a rosacea animal model, cannabidiol (CBD) significantly reduced skin redness, inflammation, and mast cell infiltration—effects that were enhanced when combined with the antibiotic metronidazole. The study identified suppression of MAPK signaling (ERK, JNK, p38) and reduced proinflammatory cytokine and chemokine production as key mechanisms in CBD’s therapeutic action.

Published in Nanomedicine, this study found that delivering CBD via intranasal nanocarriers significantly improved seizure control in rodents by enhancing targeting of the brain and accelerating onset of action—demonstrating superior effectiveness compared to conventional administration.

Published in Neuropsychopharmacology, researchers found that CBD modulates extracellular matrix-related gene expression in the brain, reducing reward-seeking behaviors tied to cocaine and caffeine exposure—indicating a potential role in curbing addiction.

Published in Inflammatory Bowel Diseases, this survey revealed that most patients with IBD feel that cannabis or CBD oil significantly improves their symptoms, including pain, appetite, sleep, and overall quality of life, with few reporting side effects.

Published in Progress in Neuro‑Psychopharmacology and Biological Psychiatry, this preclinical study in rats demonstrated that CBD (and a fluorinated derivative) significantly reduced L-DOPA–induced dyskinesia—a motor side effect of Parkinson’s treatment—without diminishing L-DOPA’s therapeutic motor benefits.

Published in Journal of Pain Management, this study found that chronic pain patients using medical marijuana experienced fewer emergency and urgent care visits and reported improved quality of life. Many users also reduced reliance on traditional pain medications.

Published in Forensic Chemistry, this research demonstrated that both THC and CBD can be detected in breath following edible consumption. Detection patterns varied significantly depending on dosage, metabolism, and time since intake, raising considerations for breath-based cannabis testing.

Published in Neurotherapeutics, this study showed that cannabidiol (CBD) protects neuronal cells in a Parkinson’s disease model by activating the Nrf2-mediated antioxidant defense pathway. The results suggest CBD may offer neuroprotective benefits in neurodegenerative conditions.

Published in Journal of Geriatric Cardiology, this study found no association between cannabis use and a higher risk of heart attacks, strokes, or other cardiovascular events among older veterans with coronary artery disease, suggesting it may not elevate cardiac risk in this population.

Published in Forensic Science International, this study found that individuals exposed to passive cannabis smoke can have detectable levels of THC and CBD in their hair — potentially impacting the accuracy of hair-based drug tests even without intentional cannabis use.

Published in Industrial Crops and Products, this study demonstrated that hemp infructescences (seeding flowers) yield significant amounts of essential oils rich in terpenes, highlighting their potential as a sustainable and valuable source of aromatic compounds for the wellness and fragrance industries.

Published in Journal of Natural Fibers, this study revealed that vortex spinning technology can produce high-quality yarn from sustainable blends of hemp and cotton—promising a more eco-friendly textile option for knitwear manufacturing.

Published in Substance Use & Misuse, this study found that heavy alcohol consumption decreased among middle-aged Californians following the legalization of recreational marijuana. The findings suggest cannabis availability may influence reductions in alcohol abuse within this demographic.

Published in Inflammatory Bowel Diseases, this survey found that most patients with inflammatory bowel disease (IBD) believe cannabis or CBD oil helps alleviate their symptoms. Respondents reported improved pain relief, appetite, sleep, and overall quality of life with minimal side effects.

Published in Movement Disorders, this clinical study demonstrated that adding CBD to standard Parkinson’s medications helped reduce motor complications like dyskinesia and overnight symptoms, without diminishing the effectiveness of the underlying therapy.

Published in Epilepsy & Behavior Reports, this study found that cannabidiol (CBD) treatment significantly reduced seizure frequency in patients with focal epilepsy—including those with tuberous sclerosis complex (TSC)—and maintained these benefits over time. Additionally, many patients were able to reduce their doses of other antiepileptic medications without an increase in adverse events.

Published in the American Journal of Preventive Cardiology, this study found that young adult users of cannabis alone showed no significant changes in heart structure or function. However, individuals who used both cannabis and nicotine experienced subtle changes in cardiac performance, suggesting that nicotine may be the driving factor.

Researchers discovered that CBD can protect human chondrocytes—cartilage cells—from ferroptosis, a form of cell death driven by oxidative stress that is increasingly linked to osteoarthritis. The findings, published in the Journal of Cellular and Molecular Medicine, highlight CBD’s potential as a therapeutic tool for joint degeneration.

In preclinical models, both CBD and THC—individually and combined—were shown to lower seizure intensity and reduce neuroinflammation. The combination offered enhanced effects, supporting the potential of cannabinoid-based therapies in epilepsy management. This study was published in the journal Pharmaceuticals.

A study published by the Journal of Affective Disorders found that adults with clinically significant anxiety and depression experienced substantial and sustained symptom relief after initiating medicinal cannabis, particularly THC-dominant products.

A food science study found that incorporating CBD and hemp flour into gluten-free cupcakes produced stable and palatable baked goods. The results suggest potential for functional foods that combine dietary preferences with cannabinoid benefits.

Cannabidiolic acid (CBDA), a non-psychoactive cannabinoid, showed greater effectiveness than the FDA-approved ALS drug riluzole in improving motor function and slowing disease progression in an animal model of amyotrophic lateral sclerosis.

Researchers found that cannabidiol (CBD) can suppress osteosarcoma, a rare and aggressive bone cancer, by interfering with inflammatory signaling pathways that promote tumor growth. The study, published by the journal Phytomedicine, suggests CBD could offer a promising adjunct treatment strategy.

A statewide survey revealed that more than one in three California adults reported recent marijuana use, with many citing daily use to help manage anxiety, depression, and sleep disturbances. Usage was especially common among adults under 40.

A chemical analysis of hemp seed oil confirmed it as a nutrient-dense food, rich in omega-3 and omega-6 fatty acids, as well as beneficial antioxidants like tocopherols. Researchers suggest the oil may have a role in supporting cardiovascular and skin health.

Scientists developed a biodegradable packaging film infused with CBD oil that resists moisture, breaks down efficiently, and exhibits strong antibacterial properties. The innovation could help reduce plastic waste while preserving food safety.

A new study demonstrated that microwave-assisted extraction yields high levels of CBD and antioxidants from cannabis leaves compared to traditional methods. The technique offers a more efficient and eco-friendly approach to cannabinoid extraction.

In a recent preclinical trial, cannabidiol (CBD) was found to significantly decrease seizure frequency and extend lifespan in mice with CDKL5 deficiency disorder, a rare and severe genetic epilepsy. The findings highlight CBD’s potential as a therapeutic candidate.

Increasing light exposure from 12 to 14 hours per day during the final two weeks of flowering led to higher yields in marijuana plants without lowering THC or CBD levels, offering growers a simple way to boost productivity.

Scientists engineered a novel nanofiber delivery platform that co-administers CBD and the antipsychotic levosulpiride directly to the brain. In animal models, the approach significantly boosted bioavailability and therapeutic efficacy for anxiety and depression.

A veterinary trial found that a combination of CBD and CBDA was well-tolerated by dogs undergoing chemotherapy for cancer. Treated dogs showed no significant adverse effects, paving the way for more research on cannabinoid use in veterinary oncology.

Preliminary findings suggest that CBDV may enhance motor and cognitive function in individuals with Rett syndrome, a rare neurological disorder. The study reported improvements in coordination, attention, and social interaction after several weeks of treatment.

CBG demonstrated cardioprotective effects in heart cells exposed to high lipid levels. The cannabinoid significantly reduced fat buildup and improved mitochondrial performance, suggesting therapeutic potential for lipid-induced heart damage.

A California-based survey found that medical-only marijuana users tend to be older, report more chronic health conditions, and use cannabis less frequently than those who consume it for both medical and recreational reasons.

A multi-center clinical study found that cannabidiol significantly lowered seizure frequency in patients with rare forms of drug-resistant epilepsy, including Lennox-Gastaut and Dravet syndromes, supporting its continued use as adjunct therapy.

Researchers found no evidence of liver toxicity in participants who used various full-spectrum and broad-spectrum cannabis oils daily for eight weeks. Liver enzyme levels remained within normal ranges, supporting the oils’ safety profiles.

A new protocol for genetically modifying cannabis plants reduced the process timeline by about 30 days. Scientists say the advancement could accelerate research into strain development and cannabinoid biosynthesis.

In vitro tests revealed that lesser-known cannabinoids CBN and CBC can inhibit breast cancer cell growth and promote apoptosis. These findings highlight their potential as therapeutic agents in oncology.

Patients who regularly consumed marijuana prior to retinal detachment surgery did not experience worse outcomes than non-users, according to new clinical data. Visual recovery rates and complication risks were comparable between groups.

New national survey data reveal that approximately 8% of U.S. cancer survivors use marijuana, with usage notably higher in states where recreational marijuana is legal. Many report using it for symptom relief, such as pain, nausea, and anxiety.

Adolescents treated with medical cannabis in a clinical setting experienced a marked reduction in tic frequency and intensity. The results suggest cannabis may be a viable treatment option for managing Tourette syndrome in younger populations.

Researchers found that subsurface drip irrigation increased CBD content and biomass yield in hemp plants while reducing water use by more than 30%. The method offers a sustainable option for improving efficiency in cannabis agriculture.

Findings suggest CBD may help mitigate alcohol dependency and its neurotoxic effects. Animal models showed reduced alcohol consumption and signs of brain protection, pointing to CBD’s potential as part of alcohol use disorder treatment.

THC accelerated wound closure and reduced inflammation in preclinical trials by altering immune cell activity. Researchers say this immunomodulatory effect could make THC a candidate for future wound treatment therapies.

A new study found that CBD significantly reduced anxiety symptoms in cats exposed to thunderstorm simulations. Improvements included decreased hiding, lower stress-related behaviors, and notably less inappropriate urination during and after storms.

Cannabidiol (CBD) and cannabidivarin (CBDV) were found to disrupt fungal cell walls and inhibit growth of several pathogenic strains, including those resistant to common antifungal drugs. The findings suggest these cannabinoids may serve as novel antifungal agents in future therapies.

Researchers found that a powdered formulation of THC and CBD dramatically improved bioavailability, delivering over twice as many cannabinoids into the bloodstream as conventional oil-based drops. This could lead to more efficient dosing and faster onset of therapeutic effects.

Survey data from nearly 2,000 people with endometriosis found that cannabis was more effective than over-the-counter or prescription medications at managing symptoms like pain, anxiety, and sleep issues. Over 90% of respondents said they would recommend cannabis to other patients.

A nanoemulsion formulation of CBD showed promise in reducing anxiety and panic behaviors in animal models. The enhanced bioavailability of this lipid-based delivery method may make it a suitable candidate for future clinical trials targeting panic disorders.

A retrospective study found that CBD-based therapies significantly reduced seizure frequency in patients with rare genetic disorders such as Rett syndrome and CDKL5 deficiency. The findings support the use of CBD in managing drug-resistant epilepsies beyond common forms.

New research found that both THC and CBD could modulate estrogen signaling and provide a protective effect against ovarian dysfunction in a preclinical model. The study points to a potential role for cannabinoids in hormone-related reproductive health.

An EEG-based study on individuals with first-episode psychosis found that cannabis use did not account for abnormal brain wave patterns often associated with the condition. The results challenge longstanding assumptions about marijuana’s role in triggering or worsening psychosis.

CBDVA, a lesser-known cannabinoid, demonstrated significant insecticidal effects against a variety of agricultural pests in lab trials. Researchers say the compound could serve as a natural alternative to conventional pesticides, pending further testing on crops and environmental safety.

New findings suggest that cannabinol (CBN) could promote brain health by reducing oxidative stress and enhancing neuronal survival. The study highlights CBN’s neuroprotective potential, particularly in conditions involving cellular damage.

Tilray has released detailed pharmacokinetic data comparing various oral and inhalable THC and CBD products. The study provides new insights into absorption rates, peak plasma concentrations, and metabolic timelines for different delivery methods.

A large-scale survey of chronic pain sufferers found that 69% used marijuana daily, with most reporting significant relief and few negative cognitive effects. Participants favored inhalation for quick relief and cited improved sleep and reduced opioid use.

Lab analysis of dozens of online-purchased CBD tinctures revealed that the majority contained significantly more or less CBD than advertised. Some products were found to contain trace amounts of THC, raising regulatory and consumer safety concerns.

Researchers in Thailand have developed a novel extraction technique that yields broad-spectrum CBD oil with minimal THC and high purity. The method enhances consistency and could improve compliance with global THC limits for therapeutic CBD products.

Researchers have developed an industrial-scale process that selectively removes THC from cannabis extracts while maintaining the integrity of other cannabinoids. The technique offers a scalable solution for producing THC-free formulations without compromising therapeutic potential.

In a clinical setting, patients given a cannabis extract containing a 1:1 ratio of THC to CBD reported notable reductions in chronic pain and improvements in overall quality of life. The study adds to the evidence supporting balanced cannabinoid profiles for pain management.

Scientists found that CBD stimulates the production of eicosanoids—lipid-based compounds involved in reducing inflammation—while THC did not produce a measurable effect. The findings underscore CBD’s unique anti-inflammatory mechanism compared to THC.

A preclinical study suggests that CBD could offer cardioprotective benefits by enhancing mitochondrial efficiency and lowering inflammation markers associated with heart failure. The results point to the cannabinoid’s potential as a supportive therapy for cardiac conditions.

An extract derived from cannabis sugar leaves was shown to have antibacterial activity against several harmful pathogens, including strains resistant to antibiotics. The study highlights a potential new use for typically discarded parts of the cannabis plant.

Scientists found that encapsulating cannabigerolic acid (CBGA) with terpenes in a nanoparticle formulation significantly enhanced pain-relieving effects in animal models. The combination also allowed for effective results at lower doses, suggesting a synergistic and more efficient approach to cannabinoid-based pain management.

A genetic analysis uncovered that specific cannabis plant parts—such as sugar leaves and bracts—exert varying influence over cannabinoid and terpene biosynthesis. The findings help explain chemical variability between strains and offer insights for targeted cultivation techniques.

A longitudinal study found that many Washington State residents ages 18–25 are tapering their cannabis use sooner than previously predicted. Researchers attributed this trend to shifting priorities, including work, education, and family life.

A side-by-side comparison revealed that whole-plant cannabis extracts outperformed isolated CBD in reducing inflammation in human keratinocyte cell cultures. Researchers say this supports the idea of the “entourage effect,” where multiple cannabis compounds work better together than alone.

In an animal model of post-traumatic epilepsy, CBD significantly reduced both seizure frequency and the extent of brain tissue damage. The study provides preclinical support for the use of CBD in preventing or mitigating epilepsy triggered by traumatic brain injury.

Research published in NeuroImage: Clinical showed that people living with HIV who use cannabis regularly exhibit more normalized brain activity in regions tied to cognition and emotion. This suggests marijuana may help counteract HIV-related neurocognitive issues.

In a study featured in Cancers, cannabidiol (CBD) was found to inhibit tumor growth in HPV-positive head and neck cancer models. It does so by enhancing immune response and reducing inflammation and markers of invasiveness.

A rodent model in Neurotherapeutics revealed that micro-dose CBD revitalizes synaptic proteins in the prefrontal cortex, reversing depression-like behaviors caused by chronic stress—indicating antidepressant potential at low dosages.

Engineers developed a 3D-printed ureteral stent infused with CBD, which delivered the compound directly to the urinary tract in rats. The localized approach effectively reduced inflammation and bacterial growth, suggesting a novel UTI treatment method.

Published in Plant Biotechnology Journal, this genetic study pinpointed key markers that determine THC and CBD levels in cannabis plants—insight that could help breeders develop strains with tailored cannabinoid profiles.

In rodent models, continuous CBD use enhanced memory performance and decreased neuroinflammatory markers. These findings, published in Brain Sciences, support the use of CBD for preserving cognitive function over time.

In a first-in-human study, healthy volunteers tolerated a combined regimen of cannabidiol and hydroxychloroquine well, with no serious side effects. Blood tests confirmed both compounds reached therapeutic levels, supporting further clinical exploration of CBD as an adjuvant therapy.

Nearly one-third of patients with drug-resistant epilepsy achieved complete seizure remission using cannabis-based formulations, according to an observational study published in Neurology. Many participants also experienced improved sleep, mood, and quality of life—while reporting minimal side effects.

Over a 12-month trial in pediatric patients, a CBD-rich oil significantly decreased seizure frequency. Most children saw sustained improvements in seizure control and overall functioning, with the treatment showing a favorable safety profile throughout the study.

This investigation revealed that cannabidiol and cannabidivarin disrupt fungal cell membranes, effectively eliminating infection-causing fungi such as Cryptococcus species and dermatophytes. The findings suggest cannabinoids may serve as natural antifungal agents.

A survey-based study found most German CBD consumers experienced positive health improvements—ranging from pain relief to better sleep—while reporting few and generally mild adverse effects. The data indicate a favorable user experience in real-world settings.

A large-scale survey revealed that over one-third of Californians report using cannabis, with most citing both mental and physical health benefits. The findings show perceived improvements in stress, sleep, and general wellbeing among users.

Analyzing national cancer registry data, researchers found a rising trend of cannabis use among cancer patients that appears unrelated to state legalization policies. It suggests growing patient-driven interest in cannabis for symptom management.

In a breakthrough extraction study, scientists developed an environmentally friendly process that increased CBD purity by 32% while significantly lowering production costs—potentially making high-grade CBD more accessible.

A national opinion poll found that most American sports fans are open to cannabis sponsorships in professional sports. Acceptance is high, especially among younger demographics, signaling potential for cannabis brands in sports marketing.

This preclinical study demonstrated that CBD reduced relapse behavior in meth-addicted rodents by modulating dopamine receptors in the brain’s reward pathways. The findings suggest CBD could support addiction recovery efforts.

Published in The Lancet Healthy Longevity, a clinical trial showed that an oromucosal spray combining THC and CBD was well tolerated by Alzheimer’s patients experiencing agitation. While results on effectiveness were mixed, participants showed no worsening in cognitive or daily functioning, suggesting the spray is safe and potentially useful in managing agitation.

A rat-based study in Progress in Neuro‑Psychopharmacology & Biological Psychiatry found that cannabidiol (CBD) restored memory performance and reversed hippocampal impairments tied to schizophrenia-like behavior. Improvements were tied to enhanced hippocampal activity and reduced oxidative damage.

Harnessing nanotechnology, researchers reported in International Journal of Pharmaceutics that binding cannabinoids to gold nanoparticles increased their delivery into breast cancer cells, leading to stronger anticancer effects compared to cannabinoids alone.

Published in Addictive Behaviors, this observational study found that regular cannabis users were significantly more likely to engage in physical exercise compared to drinking alcohol or consuming fast food. The findings suggest cannabis use may align with healthier lifestyle choices.

In a trial published in Pharmacology Biochemistry and Behavior, autistic children treated with daily CBD oil showed marked improvements in behavioral symptoms and a reduction in oxidative stress markers—offering hope for better-targeted support in ASD.

Researchers reported in Journal of Neuroscience Research that full-spectrum cannabis extract helped rebuild gut barrier integrity, reduced inflammation, and improved kidney and liver function in animal models post-stroke, indicating multi-system therapeutic potential.

Although not a cannabis study, this research in Cell Reports revealed a new LSD analog that promotes neuroplasticity and antidepressant-like effects without inducing psychedelic experiences—a promising tool for mental health.

Published in Horticulture Research, this study used far-red light supplementation at day’s end to enhance THC concentrations in cannabis plants while lowering greenhouse energy costs—an innovation in cultivation efficiency.

A rodent study in Neuropharmacology found that micro-dose CBD reversed stress-induced behavioral changes, restored synaptic proteins, and improved neuroplasticity—suggesting effective antidepressant benefits at low doses.

This study in Pharmaceutics demonstrated that CBD delivered via nanoparticles significantly alleviated panic-like behaviors in rodents, outperforming standard formulations—highlighting enhanced efficacy through nano-delivery.

Published in Canadian Journal of Public Health, this population-based study found stable rates of early cannabis initiation among Canadian youth following legalization, suggesting regulatory frameworks may not increase youth uptake.

Published in Scientific Reports, researchers observed that CBD-rich extracts led to behavioral improvements among autistic children and adolescents. Participants showed enhancements in social interaction, reductions in anxiety, and better sleep quality. The treatment was well tolerated, with only a few mild side effects reported.

Published in Behavioural Brain Research, this study found that CBC produced antidepressant-like effects in rodents, improving stress-induced behavioral deficits without affecting appetite or activity levels, suggesting it may offer a novel approach to mood disorders.

Published in Analytical Chemistry, this study demonstrated that painless microneedle patches could accurately measure THC levels in interstitial fluid, supporting a less invasive method for monitoring cannabis use.

Published in Diabetes, this cellular study found that CBD and CBG boosted insulin release from human pancreatic beta cells and offered protective effects against inflammatory damage, highlighting potential benefits for diabetes management.

Published in Journal of Geriatric Psychiatry and Neurology, this observational study found that older adult patients using medical cannabis reported significant reductions in chronic pain, anxiety, and depressive symptoms, with many decreasing reliance on traditional medications.

Published in Food Chemistry, this study revealed that THC and CBD concentrations remained largely intact after baking hemp-infused breads at typical household temperatures, indicating stability across food processing conditions.

Published in Molecular Pharmaceutics, this study found that CBD-loaded hydrogel lenses delivered consistent cannabidiol release over several days in vitro, offering promise for treating chronic eye disorders.

Published in Canadian Journal of Public Health, this population-level analysis showed that alcohol sales dropped by 7% in Nova Scotia in the first year following cannabis legalization, suggesting possible substitution effects at the community level.

Published in Journal of Cannabis Economics, this market analysis found that reducing legal cannabis prices by 10% led to a 14% increase in sales in British Columbia, highlighting price sensitivity in consumer demand.

Published in Antioxidants, this study found that a CBD-infused hydrogel accelerated skin healing, reduced inflammation, and minimized oxidative damage in rats with radiation and wound injuries. The treatment also boosted collagen production and tissue repair, highlighting its potential for dermatological and recovery applications.

Published in Journal of Clinical Endocrinology & Metabolism, this observational study found regular cannabis users had lower inflammatory markers (CRP and IL-6) compared to non-users, with no negative impact on insulin sensitivity or metabolic health.

Published in Fertility and Sterility, this large cohort study found no significant differences in sperm concentration, motility, morphology, or DNA integrity between frequent cannabis users and non-users, suggesting marijuana use doesn’t harm male fertility at usual consumption levels.

Published in Toxicology Reports, this study tested purified CBD in vitro and in animal models and found no evidence of DNA damage or mutagenesis, indicating that pure CBD is unlikely to pose genotoxic risks at therapeutic doses.

Published in Journal of Experimental Therapeutics, this study found that combining cannabinol (CBN) with the aromatase inhibitor exemestane significantly increased cancer cell death in estrogen-receptor-positive breast cancer models, suggesting potential for combination therapy.

Published in Pain Medicine, this randomized, double-blind clinical trial found that an oral blend of THC, CBD, and other cannabinoids provided superior relief from neuropathic pain compared to pregabalin, with fewer side effects such as dizziness or sedation.

Published in the Journal of Inflammation Research, this study found that cannabidiol (CBD) reduces intestinal fibrosis in ulcerative colitis by activating the Nrf2/HO-1 antioxidant pathway and suppressing inflammation through the NF-κB pathway. CBD also inhibited the TGF-β/SMAD signaling responsible for fibrosis, with its effects significantly diminished when Nrf2 was blocked.

Published in Addictive Behaviors, this systematic review of 16 longitudinal studies found that early cannabis use does not consistently increase the risk of developing substance use disorders for other drugs. While it may raise the likelihood of cannabis use disorder, the analysis found no strong evidence supporting the gateway theory linking early cannabis use to broader substance abuse.

Published in Animals, this study examined the effects of a cannabidiol-based supplement, Pain Relief™, on dogs with severe osteoarthritis. Over a 30-day period, treated dogs exhibited significant reductions in pain, as measured by the Helsinki Chronic Pain Index, along with improvements in oxidative stress markers and inflammatory cytokines—specifically, decreased interleukin-6 and increased interleukin-10 levels. No adverse effects were reported, suggesting the supplement’s potential to enhance quality of life in affected dogs.

A study published by the Institute for Work & Health (IWH) examined the impact of Canada’s 2018 legalization of adult-use marijuana on workplace cannabis consumption. The research found no significant change in the rates of employees using cannabis before or during work hours post-legalization. The authors emphasize the importance of distinguishing between off-duty use and on-the-job impairment, suggesting that workplace policies should focus on managing impairment rather than penalizing lawful, off-duty cannabis use.

Published in Pain, this National Institutes of Health-funded study found that medical marijuana is significantly more effective than prescription medications for managing chronic pain. In a comparison of over 8,500 patients, those using medical marijuana were 2.6 times more likely to report meaningful improvements in both pain and physical function. Among patients also using opioids, medical marijuana use was linked to a 39% average reduction in opioid consumption over six months.

Published in Drug Design, Development and Therapy, this study found that cannabidiol (CBD) may protect the heart from damage caused by the chemotherapy drug doxorubicin by activating the Hippo signaling pathway. In both cell and mouse models, CBD improved heart cell survival, reduced oxidative stress, and lowered cell death. These effects were reversed when the pathway was inhibited, confirming its key role in CBD’s protective action.

Published in IBRO Neuroscience Reports, this review highlights how cannabis-derived compounds, including both cannabinoids and non-cannabinoids, may address the complex pathology of Alzheimer’s disease. The authors emphasize the need for multi-target treatment strategies and identify cannabis as a promising area for future therapeutic development.

Published in Cells, this study found that cannabigerol (CBG) may help treat atopic dermatitis by suppressing key inflammatory pathways. In cell and mouse models, CBG reduced levels of multiple pro-inflammatory cytokines and inhibited the JAK/STAT and NF-κB signaling pathways, leading to improved skin condition and stronger skin barrier function.

Published in Muscle & Nerve, this study found that full-spectrum cannabidiol (CBD) oil may help treat Duchenne muscular dystrophy (DMD). In vitro tests showed dose-dependent cytotoxic effects, but in vivo administration to mdx mice at 10 mg/kg per day for 14 days was safe and led to significant improvements in muscle pathology. The treatment reduced central nuclei, IgG+ myofibers, inflammatory areas, and fibrosis in diaphragm and quadriceps muscles, while increasing myofiber size and reducing macrophage presence and NF-κB levels. Serum creatine kinase levels, a marker of muscle damage, were also lowered.

Published in Basic & Clinical Pharmacology & Toxicology, this study investigated cannabidiol’s (CBD) protective effects against cadmium-induced toxicity in mice. Researchers found that CBD mitigated oxidative stress and inflammation in the liver and kidneys by restoring antioxidant markers and reducing proinflammatory cytokines. Histological analysis confirmed tissue protection in these organs, though no protective effect was observed in testicular tissue.

Published in Human Psychopharmacology: Clinical & Experimental, this pilot study found that acute use of high-potency cannabis improved mood and reduced anxiety in young adult users without impairing their ability to regulate emotions. Participants showed no decline in performance on emotion regulation tasks while intoxicated, suggesting mood benefits without cognitive or emotional detriment.

Published as a preprint in bioRxiv, this study found that psilocybin may mitigate the effects of repetitive mild head injuries. In an animal model simulating trauma from sports, accidents, or military service, psilocybin reduced vasogenic edema, restored vascular reactivity and functional connectivity, lowered phosphorylated tau buildup, and increased levels of brain-derived neurotrophic factor (BDNF) and its receptor TrkB. These findings suggest psilocybin’s potential in addressing cognitive decline and neurodegenerative diseases associated with such injuries

Published in ACS Pharmacology & Translational Science, this study found that cannabidiol (CBD) induces apoptosis and inhibits proliferation, migration, and invasion in colorectal cancer cell lines with various mutations, including KRAS, BRAF, APC, and PTEN. The anticancer effects were mediated through CB2 receptor activation and involved endoplasmic reticulum stress, while sparing healthy intestinal organoids.

Published in the Journal of Parkinson’s Disease, this case study from the University of Geneva and Geneva University Hospital explored psilocybin-assisted psychotherapy in a 43-year-old Parkinson’s patient experiencing anxiety and difficulty accepting her diagnosis. Over four high-dose sessions across a year, the patient reported reduced pessimism and anxiety, improved well-being, and greater openness to pharmacological treatment. The study suggests psilocybin therapy may aid in emotional adjustment for Parkinson’s patients, though larger trials are needed to confirm these findings.

Published in Cannabis, this placebo-controlled study found that daily use of mucoadhesive strips containing tetrahydrocannabivarin (THCV) and cannabidiol (CBD) led to significant weight loss and metabolic improvements over 90 days. Participants experienced reductions in abdominal girth, systolic blood pressure, and LDL cholesterol, with the higher dose (16 mg THCV/20 mg CBD) showing greater efficacy.

Published in the Journal of Cannabis Research, this study surveyed 220 cancer patients enrolled in Minnesota’s medical cannabis program. While both financially comfortable and struggling patients reported significant symptom relief from cannabis use, affordability remained a major barrier. Patients facing financial hardship were more likely to spend over $200 monthly on cannabis and more likely to reduce or discontinue use due to cost, highlighting disparities in access.

Published in the Journal of Proteomics, this study found that cannabidiol (CBD) causes significant structural damage to bacterial cell walls and membranes in strains like Bacillus licheniformis, Staphylococcus aureus, and Enterococcus faecium. CBD disrupted key metabolic pathways and altered protein expression, suggesting a novel antibacterial mechanism that could serve as an alternative to traditional antibiotics.

Published in Experimental & Molecular Medicine, this study found that cannabidiol (CBD) enhances endurance exercise in mice by altering the gut microbiome and promoting muscle adaptation. CBD increased oxidative muscle fibers, mitochondrial biogenesis, and endurance-related gene expression. The study also identified Bifidobacterium animalis KBP-1 as a key microbe elevated by CBD, which independently improved running performance when administered.

Published in Pharmacology Biochemistry and Behavior, this study found that purified cannabidiol (CBD) significantly improved behavioral symptoms in children with severe, treatment-resistant autism. Ninety percent of participants showed improvement in at least one symptom, and 40% were able to reduce or discontinue other medications. Side effects were mostly mild and temporary.

Published in MedComm, this study showed that cannabidiol (CBD) improved survival and restored bone marrow function in mice exposed to radiation. The treatment reactivated stem cell maintenance pathways by upregulating the transcription factor Atf2, suggesting CBD may have value as a radioprotective therapy.

Published in the Journal of Ethnopharmacology, this study found that Moroccan cannabis essential oil reduced sensitivity to pain and aided nerve function recovery in mice with peripheral neuropathy. The effects are believed to stem from compounds like (E)-caryophyllene and α-humulene.

Published in Plants, this Cornell University study found that hot air drying at 75°C effectively reduced hemp moisture and microbial content, while glass jar curing preserved cannabinoid levels and further improved safety. The combined method was more efficient than ambient or freeze-drying approaches.

Published in Annals of the Brazilian Academy of Sciences, this study showed that CBD delivered via nanoemulsion reversed autism-like behaviors and protected hippocampal neurons in a rat model of autism. The formulation improved bioavailability and led to enhanced social interaction, reduced anxiety, and better exploratory behavior.

Published in the International Journal of Biological Macromolecules, this study found that a CBD-infused hydrogel microneedle patch reduced inflammation, skin thickness, and scaling in a mouse model of psoriasis. The treatment suppressed TRIM14 and NF-κB signaling, outperforming conventional topical medication.

Published in Health Economics, this federally funded study analyzed 16 years of county-level data and found that the presence of recreational marijuana stores was associated with a reduction in opioid-related deaths. Importantly, there was no evidence linking these stores to an increase in suicide rates or traffic fatalities.

Published in the Brazilian Journal of Medical and Biological Research, this study found that cannabidiol (CBD) reduced inflammation, oxidative stress, and tissue damage in rats after blunt chest trauma. CBD treatment lowered pro-inflammatory cytokines and improved lung structure, indicating protective effects in traumatic injury.

Published in Frontiers in Pharmacology, this study found that cannabidiol (CBD) may kill ovarian cancer cells by interfering with lipid metabolism, specifically reducing the expression of CPT1A, a key enzyme in fatty acid oxidation. The findings suggest that CBD could be a promising therapeutic candidate for targeting metabolic vulnerabilities in ovarian cancer.

Published in Pharmaceutics, this study demonstrated that cannabidiol (CBD) delivered through a nanostructured lipid carrier hydrogel protected retinal cells from degeneration in rats. The treatment reduced inflammation and oxidative stress, and the nanocarrier improved CBD bioavailability and sustained release in the eye.

Published in Health Economics Review, this study analyzed over 4,000 emergency room visits in Colorado and found that the opening of recreational marijuana stores did not lead to increased ER visits. The results challenge assumptions that legalization leads to a surge in emergency medical incidents.

Published in Journal of Neurology, this study found that a THC/CBD cannabis extract improved sleep quality in patients with Parkinson’s disease. Participants reported fewer nighttime awakenings and improved overall restfulness, with minimal side effects, suggesting the extract may offer a promising treatment for insomnia linked to the condition.

Published in Frontiers in Psychiatry, this randomized, placebo-controlled trial found that a cannabinoid-based supplement containing CBD and CBN significantly improved sleep quality in adults with subthreshold insomnia. Participants also reported better mental health and reduced stress levels, with no serious side effects reported over the 8-week study period.

Published in Molecular Neurobiology, this study found that repeated low doses of cannabinoids improved memory, cognition, and motor function in an Alzheimer’s disease mouse model. The treatment also reduced amyloid plaque levels, oxidative stress, and neuroinflammation, suggesting cannabinoids may offer therapeutic potential for neurodegenerative disorders.

Published in The Journal of Pain, this randomized, double-blind clinical trial found that low-dose cannabidiol (CBD) enhanced the pain-relieving effects of opioids in healthy adults exposed to pain stimuli. CBD also reduced pain unpleasantness and did not increase the likelihood of side effects, suggesting a safer adjunct to opioid therapy.

Published in Substance Use & Misuse, this study found that individuals with chronic pain who used cannabis daily were significantly more likely to stop using opioids compared to non-cannabis users. The analysis of nearly 9,000 participants suggested that daily cannabis use may support opioid tapering in pain management strategies.

Published in Cannabis and Cannabinoid Research, this study found that the combination of CBD, THC, and the terpene humulene exhibited strong synergistic effects against breast cancer cells. The triple combination significantly reduced cancer cell viability and migration more effectively than any compound alone, suggesting enhanced therapeutic potential.

Published in Cells, this study demonstrated that cannabidiol (CBD) and cannabigerol (CBG) inhibited the growth of HER2-positive ovarian cancer cells. The cannabinoids disrupted mitochondrial function, reduced cancer cell proliferation, and altered key signaling pathways, pointing to their promise as targeted treatments for aggressive ovarian tumors.

Published in Phytotherapy Research, this study found that a 1:1 ratio of cannabidiol (CBD) and tetrahydrocannabinol (THC) reduced the frequency and intensity of migraine attacks in patients with chronic migraines. The treatment also improved quality of life and sleep, with minimal side effects reported.

Published in Frontiers in Psychiatry, this randomized controlled trial found that individuals using a pillow cover coated with microencapsulated CBD experienced improvements in sleep duration and quality. The benefits were more pronounced among participants with sleep difficulties, suggesting a non-invasive method for CBD delivery.

Published in Microorganisms, this study showed that cannabigerol (CBG) effectively killed drug-resistant Streptococcus iniae by damaging its cell membranes. The findings suggest CBG may serve as a novel antimicrobial agent against pathogens that threaten both aquaculture and human health.

Published in Frontiers in Pain Research, this randomized controlled trial found that topical CBD gel significantly reduced pain intensity and improved jaw function in patients with temporomandibular disorder (TMD). The treatment also decreased local inflammation and was well tolerated, with no serious adverse effects reported.

Published in Toxics, this study found that a CBD-rich cannabis extract reduced markers of skin inflammation more effectively than hydrocortisone in a mouse model. The extract decreased levels of pro-inflammatory cytokines and showed antioxidant properties, suggesting it could be a safer and more effective alternative for inflammatory skin conditions.

Published in ACS Omega, this study found that cannabidiol (CBD) inhibited the growth of Streptococcus mutans, a primary bacterium responsible for tooth decay. In laboratory models, CBD reduced acid production, biofilm formation, and bacterial viability, indicating potential as a novel compound in oral hygiene products.

Published in Dermatologic Therapy, this clinical study found that topical cannabidiol (CBD) significantly reduced itching severity and improved sleep, mood, and overall quality of life in patients with atopic dermatitis. The treatment was well tolerated, with no adverse effects reported during the 4-week study period.

Published in Phytotherapy Research, this study found that cannabidiol (CBD) reduced neuropathic pain and improved memory in mice by activating serotonin 5-HT1A and cannabinoid CB1 receptors. The results suggest CBD may offer dual benefits for managing chronic pain and cognitive dysfunction.

Published in Pain Reports, this study found that medical cannabis use led to significant improvements in pain, sleep, anxiety, and physical functioning in patients with hypermobility spectrum disorders and hypermobile Ehlers-Danlos syndrome. Most patients reported better quality of life and reduced reliance on conventional medications.

Published in Antioxidants, this study found that cannabidiol (CBD) improved insulin sensitivity, glucose metabolism, and pancreatic islet structure in mice fed a high-calorie diet. CBD reduced inflammation and oxidative stress, suggesting it may help counteract metabolic disorders caused by poor diet.

Published in Frontiers in Cellular Neuroscience, this study found that CBD reduced neuronal damage in a rat model of epilepsy by preventing astrocytes from transitioning into a neurotoxic state. The results suggest a new mechanism through which CBD may offer neuroprotection in epilepsy.

Published in the International Journal of Environmental Research and Public Health, this clinical trial found that a mouthwash containing CBD and spilanthol significantly reduced gum bleeding, plaque, and inflammation in patients with gingivitis after 4 weeks of use. The treatment was safe and well tolerated.

Published in Advances in Therapy, this clinical trial found that a blend of cannabis-derived terpenes significantly reduced pain scores in patients with fibromyalgia and post-surgical pain. The terpene formulation was effective on its own and when used alongside opioids, offering a promising non-opioid pain management option.

Published in Medical Cannabis and Cannabinoids, this study found that patients with treatment-resistant epilepsy reported improvements in physical functioning, emotional well-being, and overall quality of life after using cannabis-based medicines. Many also experienced fewer seizures and reduced reliance on other medications.

Published in Pharmaceuticals, this study found that cannabidiol (CBD) strengthened the epithelial barrier in Peyer’s patches, a key immune component of the gut. In mouse models, CBD reduced gut permeability and inflammation, indicating potential for treating or preventing inflammatory bowel conditions.

Published in International Journal of Molecular Sciences, this study found that the rare cannabinoid cannabinerol (CBNR) restored normal RNA splicing in cell models affected by Alzheimer’s-related mutations. CBNR reversed gene expression abnormalities and showed potential as a therapeutic agent targeting molecular causes of neurodegeneration.

Published in Cells, this study reviewed the potential of cannabinoids to protect against glaucoma-related neurodegeneration. The authors identified multiple mechanisms, including intraocular pressure reduction, anti-inflammatory action, and neuroprotective effects, supporting the idea that cannabinoids may offer a comprehensive treatment approach for glaucoma.

Published in Frontiers in Pain Research, this meta-analysis of 43 studies concluded that medical cannabis is widely effective in managing cancer-related symptoms, especially pain, nausea, appetite loss, and sleep disturbances. The findings reflect a strong scientific consensus supporting cannabis as a safe and beneficial supportive therapy for cancer patients.

Published in Foods, this study found that adding cannabis leaves to kombucha improved its flavor, antioxidant levels, and fermentation efficiency. The cannabis-enhanced kombucha showed higher levels of beneficial compounds and better sensory scores compared to control samples, suggesting added nutritional and commercial value.

Published in Pharmaceuticals, this study demonstrated that cannabis callus extract exhibited strong antioxidant and anti-inflammatory effects in human skin cell models. The extract significantly reduced oxidative stress and inflammatory markers, supporting its potential use in skincare formulations for soothing and protective benefits.

Published in Antioxidants, this study found that nanoparticles derived from cannabis stems reduced melanin production and oxidative stress in human skin cells. The particles also showed no cytotoxic effects, highlighting their promise as a natural, safe ingredient for treating hyperpigmentation and protecting skin from environmental damage.

Published in Clinical Toxicology, this study found that veterans who used cannabis reported lower stress, better sleep, and improved coping compared to those who used alcohol. The results suggest that cannabis may offer a healthier alternative for stress management without the negative mental health effects associated with alcohol use.

Published in Applied Nanoscience, this study found that silver nanoparticles synthesized using cannabis leaf extract exhibited strong antibacterial effects against multiple pathogens and showed significant antioxidant activity. These results highlight the potential of cannabis-based nanoparticles for biomedical and environmental applications.

Published in Cureus, this study found that hospitalized COVID-19 patients who received sublingual cannabidiol (CBD) experienced shorter recovery times, reduced inflammation, and lower rates of ICU admission compared to a control group. The results suggest CBD may have therapeutic value in managing severe viral infections.

Published in Biomedicine & Pharmacotherapy, this study found that cannabidiol (CBD) protected against liver damage caused by chronic stress in mice. CBD improved mitochondrial function, reduced oxidative stress, and suppressed inflammation, leading to significant improvements in liver health.

Published in Antioxidants, this study found that CBD encapsulated in niosomes effectively protected retinal cells from oxidative stress and degeneration in animal models. The delivery system enhanced CBD stability and bioavailability, making it a promising strategy for treating degenerative eye diseases.

Published in Pharmaceuticals, this study found that a THC and CBD extract reduced neuroinflammation and promoted motor function recovery in rats with spinal cord injury. The treatment also preserved nerve tissue and reduced pain sensitivity, indicating therapeutic potential for spinal trauma.

Published in Pharmaceuticals, this study identified eleven previously unknown compounds from cannabis flowers, several of which demonstrated significant anti-tumor activity against neuroblastoma cells. Two cannabinoids showed especially strong inhibition of cancer cell viability, suggesting potential for future cancer treatments.

Published in AAPS PharmSciTech, this study found that an inhalable cannabidiol (CBD) powder formulated with methyl-β-cyclodextrin achieved high solubility, stability, and bioavailability. The powder maintained its amorphous state under humid conditions and showed promise as a fast-acting delivery system for pulmonary administration.

Published in Medical Cannabis and Cannabinoids, this study found that chronic pain patients who used medical cannabis were significantly more likely to reduce or stop opioid use, especially among those with co-occurring anxiety. Participants reported better pain management and improved mental health outcomes with cannabis treatment.

Published in Biomedicine & Pharmacotherapy, this study found that cannabidiol (CBD) helped restore normal sleep-wake cycles in mice after anesthesia-induced disruption. CBD treatment improved both the quality and timing of sleep, suggesting potential benefits for post-surgical recovery and circadian rhythm regulation.

Published in The Lancet Neurology, this study found that cannabidiol (CBD) significantly reduced seizure frequency in patients with various types of drug-resistant epilepsy. Participants experienced meaningful improvements in seizure control, with many reporting a greater than 50% reduction during treatment.

Published in Nanomedicine: Nanotechnology, Biology and Medicine, this study found that CBD-loaded nanoparticles improved glucose metabolism, reduced inflammation, and enhanced mitochondrial function in a mouse model of metabolic syndrome. The targeted delivery system increased CBD’s bioavailability and therapeutic impact.

Published in Health Economics, this study analyzed auto insurance and fatal crash data following marijuana legalization in multiple U.S. states. Researchers found no evidence that legalization led to higher accident fatality rates, increased claims, or higher average costs per claim, countering concerns about cannabis-related road risk.

Published in Expert Review of Neurotherapeutics, this long-term study found that medical cannabis significantly reduced PTSD symptoms, anxiety, and sleep disturbances in patients over an 18-month period. Most participants also reported improved overall quality of life and a decrease in the use of psychiatric medications.

Published in Cannabis and Cannabinoid Research, this study found that THC-based treatments significantly reduced motor and vocal tics in adults with Tourette syndrome. The majority of patients experienced clinical improvement with minimal side effects, suggesting cannabis as a viable therapeutic option.

Published in Biomedicine & Pharmacotherapy, this study found that tetrahydrocannabivarin (THCV) reduced food intake, body weight, and blood glucose levels in animal models of obesity and type 2 diabetes. THCV also improved insulin sensitivity, suggesting it may have therapeutic potential for metabolic disorders.

Published in Current Oncology, this study found that cannabis extracts containing high levels of cannabichromene (CBC) and tetrahydrocannabinol (THC) induced apoptosis and inhibited the growth of bladder cancer cells in vitro. The results support further investigation into these cannabinoids for cancer therapy.

Published in Plants, this Clemson University study found that far-red light enhanced the in vitro growth of marijuana plants, increasing both shoot number and biomass. The results suggest that far-red supplementation can optimize micropropagation techniques for cannabis cultivation.

Published in Children, this study found that cannabidiol (CBD) was well tolerated and significantly reduced seizure frequency in children with drug-resistant epilepsy. Caregivers also reported improvements in sleep, alertness, and behavior, supporting the use of CBD in pediatric epilepsy treatment.

Published in Scientific Reports, this study found that CBD-rich cannabis extracts improved behavioral symptoms, social interaction, and sleep quality in children and adolescents with autism spectrum disorder. The treatment was generally well tolerated, with few mild side effects reported.

Published in Journal of Psychopharmacology, this randomized clinical trial found that cannabidiol (CBD) improved verbal fluency—specifically naming function—in patients with Parkinson’s disease. The results suggest cognitive benefits in addition to CBD’s previously noted effects on mood and motor symptoms.

Published in Frontiers in Microbiology, this USDA-funded study found that hemp crude oil inhibited the growth of Fusobacterium necrophorum and Trueperella pyogenes, two bacteria that contribute to liver abscesses in cattle. The findings suggest hemp oil could be a natural alternative to antibiotics in livestock management.